Mount Sinai's Center for Alzheimer's disease at The Friedman Brain Institute provides for the integration of clinical care with advanced research efforts aimed at better understanding and treating Alzheimer’s and other forms of dementia, such as Frontotemporal Dementia.
Treatments at Mount Sinai
The Center for Cognitive Health offers comprehensive evaluation and customized management for the full spectrum of cognitive impairments. Patients coming to us typically have concerns regarding one or more of the following cognitive functions: memory, attention, language (such as aphasia and dyslexia), visual processing, decision-making, and cognition-related emotional regulation. We offer comprehensive diagnosis for a range of cognitive disorders, including neurologic and psychiatric evaluation, neuropsychological testing, brain scans (MRI, PET, AmyvidTM scans), brain electrical function testing (electroencephalography or EEG), tests of blood and cerebrospinal fluid, and genetic testing. The initial appointment is generally one hour. A customized assessment plan is then arranged for a follow-up visit. These multi-disciplinary examinations comprise the most comprehensive medical evaluation possible, providing the information we need to design a treatment plan best suited for you.
Based on the extensive information compiled during our comprehensive diagnostic assessment, we design a coordinated treatment and management plan that integrates a complete range of treatment and services. These can include: medications, cognitive rehabilitation, physical therapy, counseling, and customized patient care management.
The Center for Cognitive Health collaborates with National Football League Neurological Care (CCH-NFLNC) on a joint clinical diagnosis and care delivery practice. CCH-NFLNC is one of five such centers affiliated with the NFL. Former or current NFL players are referred to the center by staff at the NFL Central Office in Manhattan. Under the auspices of the Department of Neurology, the Center operates a fellowship program open to neurologists, psychiatrists, or rehabilitation medicine physicians. The Center’s leadership plays a key role in the development of the new subspecialty in Brain Injury Medicine that will be established by the American Board of Physical Medicine and Rehabilitation in 2014.
Mount Sinai has long been a leader in basic and clinical research of Alzheimer's Disease and other dementias. The National Institute on Aging (NIA)-Designated Mount Sinai Alzheimer's Disease Research Center (ADRC) was one of the first research centers and has been a leader in the field since its founding in 1984. We are structured into service cores (administration, education and outreach, clinical operations, neuropathology) as well as three research projects. Our projects focus on the role of biomarkers, inflammation, and vascular factors in the cause and treatment of dementia.
Scientists can learn a tremendous amount about dementia and the brain from studying healthy people as well as those with memory disorders. Therefore, we conduct several types of clinical research for healthy elders and those with memory disorders. ADRC Clinical Trials evaluate the safety and effectiveness of new medications in treating or preventing Alzheimer’s disease. Other studies examine genetic factors and biological markers, as well as factors that might either increase or decrease the risk of getting the disease.